NEWS
7 Oslo Cancer Cluster members granted funding from the Research Council
The Norwegian Research Council recently granted funding to Oslo Cancer Cluster members; BerGen Bio, Bionor Immuno, GE Healthcare, Lytix Biopharma, PCI Biotech and Phoenix Solutions.
Targovax with full year report
Oslo Cancer Cluster member Targovax will announce its fourth quarter and full year 2016 results on Thursday, 16 February 2017.
Lytix Biopharma granted 15.9 MNOK from The Research Council of Norway
Lytix Biopharma, a clinical-stage biopharmaceutical company developing novel cancer immune therapies, has been awarded a NOK 15.9 million grant from The Norwegian Research Council (User-driven Research-based Innovation) to support the investigation of LTX-315’s ability to make ’’cold tumors hot’’ and Phase II trial in Triple Negative Breast cancer (TNBC).
Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients
Survival rate of 68% from first patient cohort vs published historical rate of 30-53% suggests signal of clinical efficacy for the drug candidate. Full data set from first patient cohort to be submitted for presentation at ASCO annual meeting in June.
Lytix Biopharma granted 15.9 MNOK from The Norwegian Research Council
Oslo Cancer Cluster member Lytix Biopharma has been awarded a NOK 15.9 million grant from The Norwegian Research Council.
Phoenix Solutions granted NOK 15.8 million from the Research Council of Norway
Our member Phoenix Solutions has been granted NOK 15.8 million from the Research Council of Norway to the project “ACT for Pancreatic Cancer”.
PCI Biotech granted NOK 13.8 million from the Research Council
Our member PCI Biotech has been granted NOK 13.8 million to the project "Photochemical vaccination - novel immunotherapy concept for treatment of cancer and infectious diseases".
Cancer Crosslinks 2017 will be streamed
Cancer Crosslinks 2017 on January 26 features a really interesting program with International and Norwegian thought leaders presenting recent findings within cancer research.
Dehns is now member of the Oslo Cancer Cluster
Dehns Patent and Trade Mark Attorneys recently joined the Oslo…
